Abemaciclib (new indication: early breast cancer, HR+, HER2- patients at high risk of recurrence in combination with endocrine therapy)


  • Active Substance: Abemaciclib
  • Name: Verzenios®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: Lilly Deutschland GmbH

Time table:

  • Start: 01.05.2022
  • Final decision by G-BA: 20.10.2022

Final decision:

  • a1) Postmenopausal women: Hint for a minor additional benefit
  • a2) Premenopausal women: No additional benefit proved
  • a3) Men: No additional benefit proved